植込み型除細動器の世界市場規模：タイプ別、用途別、エンドユーザー別、地域範囲別および予測

植込み型除細動器の市場規模と予測

植込み型除細動器（ICD）市場規模は、2024年に98億8,000万米ドルと評価され、2026～2032年にかけてCAGR 3.41%で成長し、2032年には129億2,000万米ドルに達すると予測されます。

植込み型除細動器は、通常鎖骨付近の皮下に植え込まれる小型の電子機器で、心臓のリズムをモニタリングし、異常な心拍（不整脈）が検出されると電気ショックを与えます。

ICDは常に心臓をモニタリングし、危険な不整脈が発生した場合には電気ショックを与えて正常な心臓のリズムを回復させています。典型的なICDはパルス発生器と心臓に電気ショックを与える1本以上のリード線（ワイヤ）で構成されています。

ICDは、心停止、心室細動、ある種の心不全の既往歴がある患者など、生命を脅かす不整脈のリスクがある患者に配合されます。

植込みは通常、局所麻酔下で行われ、リード線を心室に、パルスジェネレーターを皮下に設置します。

ICDは心臓のリズムを継続的にモニターし、不整脈エピソードのデータを記録します。技術の進歩により、ICDはより小型で高性能になり、診断機能が強化され、バッテリーの寿命も長くなりました。

ICDは、心室頻拍や細動のような生命を脅かす不整脈を検出すると、心臓に高エネルギーのショックを与え、心臓の正常なリズムを回復させています。

一部のICDにはペースメーカー機能もあり、必要に応じて適切な心拍数を維持するためのペーシングパルスを送ることができます。

最新のICDは遠隔モニタリング機能を備えており、ヘルスケアプロバイダが患者の心臓リズムや機器の機能を遠隔でモニタリングできるため、潜在的な問題の早期発見が可能になり、頻繁な診療の必要性が軽減されます。

植込み型除細動器の世界市場力学

植込み型除細動器の世界市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

心血管疾患の発生率の増加：心不全や不整脈を含む心血管疾患の有病率の上昇は重要な促進要因です。これらの疾患は世界的に多くの人口に影響を与え続けているため、救命機器としてのICDの需要も増加しています。

技術の進歩小型化、電池寿命の延長、診断機能の強化、不整脈検出アルゴリズムの改善など、ICD技術の絶え間ない進歩が市場成長の原動力となっています。これらの技術革新は、機器の有効性と患者の予後を改善します。

高齢化人口の増加：高齢化社会への人口動態の変化は、心臓疾患の発生率の上昇に寄与しています。高齢者は不整脈や突然の心停止を起こしやすいため、これらの症状を管理するICDの需要が高まっています。

意識とヘルスケアインフラの拡大：先進国、発展途上国を問わず、心臓の健康に対する意識の高まりと先進的ヘルスケアインフラの整備がICDsの普及を後押ししています。また、ヘルスケアサービスへのアクセス向上も、ICD植込みによる早期診断・治療を後押ししています。

規制当局のサポートと償還施策：多くの国々で、ICD治療へのアクセスを容易にする規制の枠組みや償還施策が整備されています。そのため、ヘルスケアプロバイダはICDを配合し、患者はICDの植込み手術を受けるようになり、市場の成長を後押ししています。

ライフスタイルの変化とリスク要因：座りがちな生活習慣、不健康な食生活、高いストレスレベルを特徴とするライフスタイルの変化は、心血管疾患の蔓延に寄与しています。このようなライフスタイルの変化は不整脈や突発的な心疾患のリスクを増大させるため、予防的・治療的介入としてのICDの需要を促進しています。

技術統合と遠隔モニタリング：ICDとワイヤレス接続や遠隔モニタリングシステムなどの先進技術の統合は、患者管理を改善し、治療成績を向上させています。これらの機能により、ヘルスケアプロバイダは患者の心臓の健康状態を遠隔でモニターすることができ、タイムリーな介入を保証し、頻繁な通院に伴う医療費を削減することができます。

主要課題

高コスト：ICDの機器や植込み手術には多額の費用がかかるため、低所得層の患者や予算に制約のあるヘルスケアシステムのアクセスが制限されます。

技術の複雑さ：技術の進歩にもかかわらず、ICDは複雑であるため、植込みや管理には専門的なトレーニングが必要であり、医療従事者には困難が伴い、手技のリスクも増大します。

機器の合併症：ICDはリードの脱落、植込み部位の感染、機器の誤作動などの合併症に遭遇する可能性があります。これらの問題は、追加手術の必要性、患者の転帰への影響、ヘルスケアコストの増加をもたらします。

バッテリーの寿命と交換：バッテリーの技術は進歩しているが、ICDはバッテリーの消耗により定期的な交換が必要です。これには外科的処置とそれに伴うリスク、コストが伴う。

患者の選択と管理ICD植込みの適切な候補者の選択と植込み後の患者の管理には、リスクとベネフィットの慎重な評価が必要です。年齢、併存疾患、ライフスタイルの選択などの要因は、患者の転帰や機器の有効性に影響を与えます。

規制上の課題：規制要件を遵守し、進化する基準へのコンプライアンスを確保することは、メーカーや医療提供者にとって困難な課題です。規制の枠組みの変化は、機器の承認や市場参入戦略に影響を与える可能性があります。

倫理的考察：生命を脅かす病態を管理するために植え込まれたデバイスを使用する患者の適切な選択、同意、終末期医療の決定に関して、倫理的ジレンマが生じる可能性があります。

競争と市場力学：機器メーカー間の激しい競争は、一部の地域では市場が飽和状態にあることと相まって、価格設定と市場シェアを管理しながら継続的な技術革新を行うよう企業に圧力をかける可能性があります。

主要動向

技術の進歩：ICD技術の継続的な革新には、小型化、電池寿命の向上、不整脈検出のための先進的アルゴリズム、遠隔モニタリングや患者管理のためのデジタルヘルスプラットフォームとの統合などが含まれます。

皮下ICD（S-ICD）へのシフト：S-ICDはリード線を心臓内に挿入する必要がないため、経静脈的リード線に伴う合併症のリスクが軽減されます。S-ICDは、血管へのアクセスが限られている患者や感染症のリスクが高い患者にとって代替となります。

個別化医療：個別化治療への注目が高まるにつれ、心拍パターン、基礎疾患、ライフスタイルなど、患者固有の要因によるICD治療のカスタマイズが推進されています。

遠隔モニタリングと接続性の強化：ICDとワイヤレスとモバイル技術の統合により、心臓のリズムや機器の機能をリアルタイムで遠隔モニタリングすることが可能になります。この動向は、不整脈の早期発見や機器に関連する問題の事前管理を容易にし、患者ケアを向上させています。

高齢化人口の増加：高齢化社会への人口動態の変化は、心血管系疾患や不整脈の発生率の上昇に寄与し、予防と治療ソリューションとしてのICDの需要を増大させています。

適応の拡大：ICD治療の適応が従来型一次予防や二次予防から、非虚血性心筋症や特定の遺伝性不整脈症候群の高リスク患者に拡大することで、市場の可能性が拡大します。

患者の転帰の重視：患者教育、生活習慣の改善、ICD治療と並行した心血管健康の統合管理など、包括的なケアパスを通して患者の転帰を改善することに重点を置きます。

規制と償還状況：進化する規制の枠組みと償還施策は市場力学に影響を与え、機器の承認、市場参入、各地域での普及率に影響を与えます。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 植込み型除細動器市場：タイプ別

• シングルチャンバーICD
• デュアルチャンバーICD
• 心臓再同期療法除細動器

第5章 植込み型除細動器市場：用途別

• 心室細動
• 不整脈

第6章 植込み型除細動器市場：エンドユーザー別

• 心臓センター
• 外来手術センター

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Medtronic
• Abbott
• Boston Scientific
• BIoTronik
• LivaNova PLC
• MicroPort Scientific Corporation
• Koninklijke Philips N.V.（Philips Healthcare）
• ZOLL Medical Corporation
• Medico S.p.A.
• Progetti Srl.

第11章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 供給源と参考文献

Implantable Cardioverter Defibrillators Market Size And Forecast

Implantable Cardioverter Defibrillators Market size was valued at USD 9.88 Billion in 2024 and is projected to reach USD 12.92 Billion by 2032, growing at a CAGR of 3.41% from 2026 to 2032.

Implantable Cardioverter Defibrillators (ICDs) are small electronic devices implanted under the skin, usually near the collarbone, to monitor heart rhythms and deliver electric shocks when abnormal heartbeats (arrhythmias) are detected.

ICDs continuously monitor the heart and deliver electrical shocks to restore normal heart rhythm if dangerous arrhythmias occur. A typical ICD consists of a pulse generator and one or more leads (wires) that deliver electrical shocks to the heart.

ICDs are prescribed for patients at risk of life-threatening arrhythmias, such as those with a history of cardiac arrest, ventricular fibrillation, or certain types of heart failure.

Implantation is typically performed under local anesthesia, involving the placement of leads in the heart's chambers and the pulse generator under the skin.

ICDs continuously monitor heart rhythms and record data on arrhythmia episodes, which can be reviewed by healthcare providers during follow-up visits. Technological advancements have led to smaller, more sophisticated ICDs with enhanced diagnostic capabilities and longer battery life, improving patient outcomes and quality of life.

ICDs deliver high-energy shocks to the heart when they detect life-threatening arrhythmias like ventricular tachycardia or fibrillation, restoring the heart's normal rhythm.

Some ICD models also include pacemaker functionality, capable of delivering pacing pulses to maintain appropriate heart rates when needed.

Modern ICDs feature remote monitoring capabilities, allowing healthcare providers to monitor patients' heart rhythms and device function remotely, enabling early detection of potential issues and reducing the need for frequent clinic visits.

Global Implantable Cardioverter Defibrillators Market Dynamics

The key market dynamics that are shaping the global implantable cardioverter defibrillators market include:

Key Market Drivers

Increasing Incidence of Cardiovascular Diseases: The rising prevalence of cardiovascular diseases, including heart failure and arrhythmias, is a significant driver. As these conditions continue to affect a larger population globally, the demand for ICDs as life-saving devices also increases.

Advancements in Technology: Continuous advancements in ICD technology, such as miniaturization, longer battery life, enhanced diagnostic capabilities, and improved algorithms for arrhythmia detection, drive market growth. These innovations improve device effectiveness and patient outcomes.

Growing Aging Population: The demographic shift towards an aging population is contributing to higher incidences of heart diseases. Elderly individuals are more prone to arrhythmias and sudden cardiac arrest, thereby increasing the demand for ICDs to manage these conditions.

Expanding Awareness and Healthcare Infrastructure: Increasing awareness about cardiac health and the availability of advanced healthcare infrastructure in developed and developing countries are driving the adoption of ICDs. Improved access to healthcare services also supports early diagnosis and treatment with ICD implantation.

Regulatory Support and Reimbursement Policies: Favorable regulatory frameworks and reimbursement policies in many countries facilitate access to ICD therapy. This encourages healthcare providers to prescribe ICDs and patients to undergo implantation procedures, boosting market growth.

Lifestyle Changes and Risk Factors: Changing lifestyles characterized by sedentary habits, unhealthy diets, and high-stress levels contribute to the prevalence of cardiovascular diseases. These lifestyle factors increase the risk of arrhythmias and sudden cardiac events, thereby driving the demand for ICDs as preventive and therapeutic interventions.

Technological Integration and Remote Monitoring: Integration of ICDs with advanced technologies, such as wireless connectivity and remote monitoring systems, improves patient management and enhances treatment outcomes. These features enable healthcare providers to monitor patients' cardiac health remotely, ensuring timely intervention and reducing healthcare costs associated with frequent clinic visits.

Key Challenges

High Cost: The cost of ICD devices and implantation procedures can be substantial, limiting access for patients in lower-income brackets and healthcare systems with budget constraints.

Technological Complexity: Despite advancements, the complexity of ICD technology requires specialized training for implantation and management, posing challenges for healthcare providers and increasing procedural risks.

Device Complications: ICDs may encounter complications such as lead dislodgement, infection at the implant site, and device malfunction. These issues can necessitate additional surgeries, impact patient outcomes, and increase healthcare costs.

Battery Life and Replacement: While battery technology has improved, ICDs still require periodic replacement due to battery depletion. This involves surgical procedures and associated risks, as well as costs.

Patient Selection and Management: Selecting appropriate candidates for ICD implantation and managing patients post-implantation require careful assessment of risks versus benefits. Factors such as age, comorbidities, and lifestyle choices influence patient outcomes and device effectiveness.

Regulatory Challenges: Adherence to regulatory requirements and ensuring compliance with evolving standards can be challenging for manufacturers and healthcare providers. Changes in regulatory frameworks may impact device approvals and market entry strategies.

Ethical Considerations: Ethical dilemmas may arise regarding appropriate patient selection, consent, and end-of-life care decisions for individuals with implanted devices designed to manage life-threatening conditions.

Competition and Market Dynamics: Intense competition among device manufacturers, coupled with market saturation in some regions, may pressure companies to innovate continuously while managing pricing and market share.

Key Trends:

Technological Advancements: Continuous innovation in ICD technology includes miniaturization, improved battery life, advanced algorithms for arrhythmia detection, and integration with digital health platforms for remote monitoring and patient management.

Shift towards Subcutaneous ICDs (S-ICDs): There is a growing preference for S-ICDs, which do not require leads to be placed inside the heart, reducing the risk of complications associated with transvenous leads. S-ICDs offer an alternative for patients with limited vascular access or higher risks of infection.

Personalized Medicine: Increasing focus on personalized treatment approaches drives the customization of ICD therapy based on patient-specific factors such as heart rhythm patterns, underlying conditions, and lifestyle considerations.

Enhanced Remote Monitoring and Connectivity: Integration of ICDs with wireless and mobile technologies enables real-time remote monitoring of cardiac rhythms and device function. This trend enhances patient care by facilitating early detection of arrhythmias and proactive management of device-related issues.

Growing Aging Population: The demographic shift towards an aging population contributes to a higher incidence of cardiovascular diseases and arrhythmias, increasing the demand for ICDs as a preventive and therapeutic solution.

Expansion of Indications: Broadening indications for ICD therapy beyond traditional primary and secondary prevention to include high-risk patients with non-ischemic cardiomyopathy and certain inherited arrhythmia syndromes expands the market potential.

Focus on Patient Outcomes: Emphasis on improving patient outcomes through comprehensive care pathways, including patient education, lifestyle modifications, and integrated management of cardiovascular health alongside ICD therapy.

Regulatory and Reimbursement Landscape: Evolving regulatory frameworks and reimbursement policies influence market dynamics, affecting device approvals, market access, and adoption rates across different regions.

Global Implantable Cardioverter Defibrillators Market Regional Analysis

Here is a more detailed regional analysis of the global implantable cardioverter defibrillators market:

North America

North America is significantly dominating the implantable cardioverter defibrillators market and is expected to continue its growth throughout the forecast period, owing to several variables. North America boasts a well-developed healthcare system with advanced medical facilities, including specialized cardiac centers and hospitals equipped to perform complex cardiac procedures such as ICD implantation.

The region has a notably high prevalence of cardiovascular diseases (CVDs), including coronary artery disease, heart failure, and arrhythmias. This high disease burden necessitates a robust market for cardiac devices like ICDs to manage and treat these conditions effectively.

North American companies are at the forefront of ICD innovation. They invest heavily in research and development (R&D) to enhance device capabilities, improve longevity, reduce complications, and incorporate advanced features such as remote monitoring and connectivity.

The regulatory environment in North America, particularly the United States through the FDA (Food and Drug Administration), facilitates efficient device approvals and market access. Clear regulatory pathways encourage innovation and expedite the introduction of new ICD technologies to the market.

The region benefits from a strong emphasis on biomedical research and innovation. Academic institutions, research centers, and private sector companies collaborate to drive advancements in cardiac care technologies, including ICDs.

Most North American countries have well-established healthcare insurance systems that provide broad coverage for medical devices and procedures, including ICD implantation. This ensures that eligible patients have access to ICD therapy without significant financial barriers.

Continuous medical education programs and professional development initiatives ensure that healthcare providers are well-trained in the latest ICD technologies and treatment protocols. This enhances patient care and contributes to high adoption rates of ICDs.

North American companies often have extensive global market presence and strategic partnerships with healthcare providers, distributors, and research institutions worldwide. This enables them to leverage economies of scale and effectively meet global demand for ICDs while maintaining technological leadership.

Asia Pacific

Asia Pacific is emerging as the fastest-growing region in the Implantable Cardioverter Defibrillators (ICD) market. The region is experiencing an increasing prevalence of cardiovascular diseases (CVDs) such as coronary artery disease and arrhythmias, driven by aging populations, sedentary lifestyles, and changing dietary habits.

Investments in healthcare infrastructure and expansion of specialized cardiac care facilities are improving access to advanced medical treatments, including ICD implantation.

Rising healthcare literacy and awareness about cardiovascular health are prompting earlier diagnosis and treatment of heart conditions, leading to higher demand for ICDs as life-saving devices.

Economic development and urbanization in countries across the Asia Pacific are contributing to lifestyle changes associated with higher CVD risk factors, such as obesity and hypertension, driving the need for cardiac interventions like ICDs.

The adoption of advanced medical technologies, including ICDs with improved battery life, smaller form factors, and enhanced functionalities, is increasing due to technological advancements and greater acceptance by healthcare providers and patients.

Supportive government policies, initiatives to enhance healthcare access, and efforts to strengthen regulatory frameworks for medical devices are facilitating market growth and improving patient outcomes.

Rising healthcare expenditure and expanding insurance coverage in many countries within the Asia Pacific are enabling more patients to afford ICD therapy, reducing financial barriers to treatment.

Collaboration between global medical device manufacturers, local healthcare providers, and distribution networks is accelerating market penetration and ensuring the availability of advanced cardiac care technologies across the region.

Global Implantable Cardioverter Defibrillators Market: Segmentation Analysis

The Global Implantable Cardioverter Defibrillators Market is segmented based on Type, Application, End User, And Geography.

Implantable Cardioverter Defibrillators Market, By Type

• Single Chamber ICDs
• Dual Chamber ICDs
• Cardiac Resynchronization Therapy Defibrillators

Based on Type, the market is bifurcated into Single Chamber ICDs, Dual Chamber ICDs, Cardiac Resynchronization Therapy Defibrillators. The Dual Chamber ICDs segment dominates the market due to its ability to provide more accurate detection and treatment of arrhythmias compared to Single Chamber ICDs. Dual Chamber ICDs offer improved synchronization between the atrium and ventricle, enhancing therapeutic outcomes, especially in patients with complex arrhythmias requiring precise management.

Implantable Cardioverter Defibrillators Market, By Application

• Ventricular Fibrillation
• Arrhythmias

Based on Technology, the market is bifurcated into Ventricular Fibrillation, Arrhythmias. In the Implantable Cardioverter Defibrillators (ICD) market, the Ventricular Fibrillation (VF) application segment dominates. VF is a critical and life-threatening arrhythmia that can lead to sudden cardiac arrest. ICDs are specifically designed to detect and treat VF promptly, making them essential for preventing cardiac emergencies and improving patient survival rates in such cases.

Implantable Cardioverter Defibrillators Market, By End-User

• Hospitals
• Cardiac Centers
• Ambulatory Surgical Centers

Based on End-Users the market is bifurcated into Hospitals, Cardiac Centers, Ambulatory Surgical Centers. In the Implantable Cardioverter Defibrillators (ICD) market, Hospitals dominate as the primary end-user segment. Hospitals possess specialized cardiac units, skilled healthcare professionals, and comprehensive infrastructure necessary for diagnosing, implanting, and managing ICDs. They offer a full spectrum of cardiac care services, making them the preferred choice for complex medical interventions like ICD implantation.

Implantable Cardioverter Defibrillators Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on Geography, the Global Implantable Cardioverter Defibrillators Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Asia Pacific dominates the Implantable Cardioverter Defibrillators (ICD) market. This is due to factors such as advanced healthcare infrastructure, high prevalence of cardiovascular diseases, robust technological advancements, favorable reimbursement policies, and a proactive approach towards adopting innovative medical technologies, all contributing to greater market penetration and adoption rates in the region.

Key Players

The "Global Implantable Cardioverter Defibrillators Market" study report will provide valuable insight emphasizing the global market. The major players in the market are Medtronic, Abbott, Boston Scientific, Biotronik, LivaNova PLC, MicroPort Scientific Corporation, Koninklijke Philips N.V. (Philips Healthcare), ZOLL Medical Corporation, Medico S.p.A., Progetti Srl.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In September 2022, Kauvery Hospital inaugurated the Restart Heart Foundation in Chennai, India, deploying more than 100 automated external defibrillators at strategic locations across the city.
• In August 2022, Medtronic reported successful trial outcomes for its investigational EV ICD (extravascular implantable cardioverter defibrillator) system. This device is designed to mitigate certain risks associated with traditional transvenous ICDs by placing its lead outside the heart and veins, beneath the sternum, using a minimally invasive approach.

TABLE OF CONTENTS

1. INTRODUCTION

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Implantable Cardioverter Defibrillators (ICD) Market, By Type

• Single Chamber ICDs
• Dual Chamber ICDs
• Cardiac Resynchronization Therapy Defibrillators

5. Implantable Cardioverter Defibrillators (ICD) Market, By Application

• Ventricular Fibrillation
• Arrhythmias

6. Implantable Cardioverter Defibrillators (ICD) Market, By End User

• Cardiac Centers
• Ambulatory Surgical Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Medtronic
• Abbott
• Boston Scientific
• Biotronik
• LivaNova PLC
• MicroPort Scientific Corporation
• Koninklijke Philips N.V. (Philips Healthcare)
• ZOLL Medical Corporation
• Medico S.p.A.
• Progetti Srl.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References